Point of Care Diagnostics
XING Technologies is an Australian-based biotechnology company specialising in transformative diagnosis and monitoring technologies for cancer and disease.
The company’s proprietary nanotechnologies are transforming the future practice of medicine and enabling personalised healthcare. XING’s service and product lines currently span from cancer care to rapid nucleic acid extraction, protein detection diagnostics and nanoparticle capture agents to identify and prevent the spread of infectious diseases.
XING Genomic Services receives NATA accreditation for Pillar Biosciences HRD Gene Panel Enabling Cost-Effective PARPi-response Prediction
Brisbane, Australia – XING Genomic Services, a subsidiary of XING Technologies, is excited to announce that they have received NATA accreditation effective from July 9, 2021 to offer clinical cancer genetics testing using the Pillar Biosciences HRD (homologous recombination deficiency) test. This test identifies cancer patients whose tumours cannot repair DNA damage, making them more likely to respond to PARP inhibitors. This test was clinically validated in breast and ovarian tumours and is being used in a screening test to determine patient eligibility in a phase 2 clinical trial which is testing PARP inhibitor efficacy in a subset of breast and ovarian cancer patients for whom PARP inhibitors are not yet approved.
Read More >>